The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...
Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...